Phaseline

Companies › Sinomune Pharmaceutical

Sinomune Pharmaceutical: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Infectious disease, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ZYG24002–Phase 1Seborrheic DermatitisDec 2026
ZYG24004 1% topical film-forming formulation–Phase 1Tinea PedisJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07404033ZYG24002Phase 1Seborrheic DermatitisImmunologyDec 2026
NCT07668999ZYG24004 1% topical film-forming formulationPhase 1Tinea PedisInfectious diseaseJun 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.